Qiagen NV (QGEN) Shares Bought by Van ECK Associates Corp

Qiagen NV (QGEN) Shares Bought by Van ECK Associates Corp

Several other large investors have also recently added to or reduced their stakes in QGEN. Dimensional Fund Advisors LP increased its stake in Qiagen NV by 58.3% in the fourth quarter. Dimensional Fund Advisors LP now owns 72,909 shares of the company’s stock worth $2,043,000 after buying an additional 26,838 shares during the period. Private Advisor Group LLC increased its stake in Qiagen NV by 2.8% in the fourth quarter. Private Advisor Group LLC now owns 9,431 shares of the company’s stock worth $264,000 after buying an additional 258 shares during the period. State Street Corp increased its stake in Qiagen NV by 4.4% in the fourth quarter. State Street Corp now owns 2,287,457 shares of the company’s stock worth $64,092,000 after buying an additional 95,778 shares during the period. Brown Capital Management LLC increased its stake in Qiagen NV by 6.6% in the fourth quarter. Brown Capital Management LLC now owns 999,760 shares of the company’s stock worth $28,013,000 after buying an additional 61,539 shares during the period. Finally, Wetherby Asset Management Inc. increased its stake in Qiagen NV by 4.2% in the fourth quarter. Wetherby Asset Management Inc. now owns 9,110 shares of the company’s stock worth $256,000 after buying an additional 367 shares during the period. 60.68% of the stock is owned by hedge funds and other institutional investors.

Van ECK Associates Corp boosted its position in Qiagen NV (NASDAQ:QGEN) by 2.5% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 539,805 shares of the company’s stock after buying an additional 13,059 shares during the period. Van ECK Associates Corp’s holdings in Qiagen NV were worth $15,638,000 at the end of the most recent reporting period.

Qiagen NV (NASDAQ QGEN) opened at 33.74 on Thursday. The stock has a market capitalization of $7.68 billion, a PE ratio of 93.72 and a beta of 1.05. Qiagen NV has a 12 month low of $20.71 and a 12 month high of $33.83. The company’s 50-day moving average price is $31.02 and its 200 day moving average price is $29.46.

A number of equities research analysts recently commented on the company. Commerzbank Ag reaffirmed a “buy” rating on shares of Qiagen NV in a report on Monday. DZ Bank AG reaffirmed a “neutral” rating on shares of Qiagen NV in a report on Monday. Barclays PLC reaffirmed a “buy” rating and set a $33.00 target price on shares of Qiagen NV in a report on Monday, May 15th. Evercore ISI lifted their target price on Qiagen NV from $30.00 to $31.50 and gave the stock an “outperform” rating in a report on Thursday, May 4th. Finally, Deutsche Bank AG reaffirmed a “buy” rating on shares of Qiagen NV in a report on Tuesday, May 2nd. Seven equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $28.36.

About Qiagen NV

QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:QGEN”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Want to see what other hedge funds are holding QGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Qiagen NV (NASDAQ:QGEN).

Related posts

Leave a Comment